Objective: Although gout has recognized prevention and treatment options, some patients have recurrent unplanned hospital admissions with gout flares. The aim of this study was to identify factors associated with recurrent hospital admissions with gout. Methods: A 1:1 case-control study was designed; cases were patients with 2 or more gout-related hospital admissions during any 12-month period between 2002 and 2007 (n ϭ 48). Each case was matched with an age, sex and ethnicity-matched control patient with gout but without hospital admission, identified from the rheumatology clinic (n ϭ 48). Results: Patients with recurrent hospital admissions had a higher number of comorbid medical conditions, particularly higher rates of heart disease (odds ratio 2.9, P ϭ 0.013). Cases also had more hospital admissions for other medical problems (mean number of admissions in the preceding year 5.8 vs. 0.6, P Ͻ 0.0001). Although cases had higher rates of tophaceous disease and higher serum urate concentrations, there was no difference in gout disease duration. Cases were less likely to be on allopurinol (odds ratio 0.06, P Ͻ 0.0001), and those on allopurinol were on lower doses (median dose 200 mg/d vs. 300 mg/d, P ϭ 0.0019). Conclusion: Medical comorbidity, hyperuricemia, and inadequate allopurinol use are associated with repeated unplanned hospitalization for gout. These data suggest that the use of intensive urate-lowering therapy may prevent such admissions.
C enturies of research have led to good understanding of the pathophysiology of gout. High serum urate (SU) concentrations result in the formation and deposition of monosodium urate crystals in joint structures and in other sites in the form of tophi. The most characteristic features of gout are acute attacks of joint inflammation, particularly affecting the first metatarsophalangeal joint. Polyarticular flares can also occur, and if untreated or poorly managed, the disease can become chronic and disabling. Urate-lowering therapies such as allopurinol can prevent gout flares and chronic tophaceous gout. [1] [2] [3] [4] In recent years, there have been comprehensive guidelines published on the management of gout, focusing on the importance of long-term preventive therapy. 5, 6 Despite these resources, many patients with gout have recurrent flares and disability related to chronic disease. 7, 8 In particular, some patients require repeated hospitalizations with gout flares. This is a clinically important group of patients due to their poor disease control and high health care utilization. The factors associated with such unplanned hospital admissions have not been reported. The aim of this study was to identify the patient, disease, and management factors associated with recurrent hospital admissions for management of gout.
METHODS
We performed a case-control study of patients with gout in our institution (Counties Manukau District Health Board, South Auckland, New Zealand). This retrospective study was designed to determine the factors associated with recurrent hospital admission for gout. Ethical approval for this study was provided by Northern X Regional Ethics Committee.
All patients admitted between 2002 and 2007 with a primary diagnosis of gout were identified from hospital discharge records (ICD-10 codes M10.0, M10.4, M10.9). For the purpose of this study, cases were defined as all patients with 2 or more unplanned hospital admissions for gout management during any 12-month period between 2002 and 2007 (n ϭ 48). Patients with admissions for rheumatic disease other than gout were not included in the analysis.
A 1:1 case-control study design was created by matching each case with an age, sex and ethnicity-matched patient with gout who had no gout-related hospital admissions (n ϭ 48). Control patients were identified from a database of patients attending hospital outpatient rheumatology clinics for management of gout. For each case, the potential pool of control patients was allocated a random number. The patient with the highest random number was chosen as the control. All patients (cases and controls) included in the analysis had a history of acute gout confirmed by a physician, and also by the Wallace/American College of Rheumatology preliminary diagnostic criteria for acute gout. 9 Inpatient and outpatient chart review was undertaken and history, examination, laboratory, and gout treatment variables were recorded for each patient. Gout was recorded as tophaceous if subcutaneous tophi were present. Erosive disease was recorded if there were erosions visible on available plain radiographs (radiographs available for 60% cases vs. 85% controls). Patients' SU concentration (mmol/L) was recorded at the time of the admission. In the case of control patients, the closest available measurement to the comparison date was used. Long-term colchicine prophylaxis was defined as any patient on regular colchicine between episodes of acute gout. Allopurinol therapy was similarly defined as any patient prescribed regular allopurinol between episodes of acute gout. Use of uricosuric agents was also recorded.
Comorbid medical conditions were recorded from the patient's last hospital discharge summary or clinic letter. Coronary heart disease, congestive heart failure, and valvular heart disease were recorded as the variable "heart disease."
Three key areas were chosen for analysis: medical comorbidities, gout characteristics, and gout management. To ensure adequate matching, the same 12-month period was analyzed for each case and its matched control.
Data were analyzed using SPSS version 13 (SPSS Inc., Chicago, IL). The Student t test or Wilcoxon independent groups test were used as appropriate with odds ratios (OR) calculated using the Mantell-Haenszel method. Data were complete for all variables except for radiographic data. Patients with missing radiographic data were excluded from analysis involving this variable but were included in all other analyses in an intention to treat analysis.
RESULTS

Patient and Admission Characteristics
There were a total of 940 gout-related unplanned hospital admissions involving 707 patients in the 5-year period. Of this group, 48 patients (cases) were admitted 2 or more times within a 12-month period and had a total of 257 admissions in 5 years. The average (SD) length of stay for these admissions was 2.8 (1.1) days. Virtually all of the recurrent admissions were for management of acute gout flares, with only 1 admission for management of an infected tophus.
The mean (SD) age for both the cases and controls was 60 (16) years. In both groups, there were 36 men (75%), and the majority of patients in each group (42/48, 88%) were of Maori or Pacific ethnicity.
Medical Comorbidities
Both the cases and controls had high rates of medical comorbidity (Table 1) . However, patients with recurrent hospital admissions for gout had a greater number of total comorbid medical conditions, particularly higher rates of heart disease (OR 2.9, P ϭ 0.013). Rates of diabetes, dyslipidaemia, and hypertension were similar between the 2 groups. Both the cases and controls also had high rates of chronic renal impairment, with nearly two-third of patients having at least moderate reduction in their glomerular filtration rate.
Cases also had very high rates of hospital admission for other medical conditions (5.8 vs. 0.6 admissions in the preceding year, P Ͻ 0.0001). There was a higher rate of aspirin use in the cases (OR 2.3, P ϭ 0.041), but no significant differences in diuretic use or rates of polypharmacy between the 2 groups.
Gout Characteristics and Treatments
There was no difference in disease duration or rheumatology clinic consultation between the 2 groups ( Table 2 ). Gout disease Cases were less likely to be on allopurinol (OR 0.06, P Ͻ 0.0001), and those on allopurinol were on lower doses (median dose 200 mg vs. 300 mg, P ϭ 0.0019). Long-term colchicine prophylaxis was also prescribed less frequently in those with recurrent hospital admissions (OR 0.39, P ϭ 0.039). No uricosuric agents were used by these patients.
DISCUSSION
This work has identified a number of factors associated with recurrent unplanned hospital admissions for gout. Patients with recurrent admissions for gout have higher rates of comorbid medical conditions and admission for other medical conditions compared with matched controls. Despite similar access to ambulatory rheumatology services, those with recurrent hospital admissions for gout also have features of more severe gout, with higher rates of erosive and tophaceous disease. Furthermore, a key feature of those with recurrent hospital admissions is inadequate long-term management of gout, with low rates of urate-lowering therapy and colchicine prophylaxis.
Although gout treatment guidelines have been published, recent studies of doctors' prescribing have shown poor concordance with treatment guidelines 10 and suboptimal use of urate-lowering therapies. [11] [12] [13] [14] [15] [16] Our finding of suboptimal urate-lowering therapy is consistent with a recent US study which reported that only 27% of hospitalized patients with gout were on allopurinol before admission. 17 None of these studies to date (including the current study) take into account patient adherence to therapy so the actual number of patients correctly taking urate-lowering therapy may be much lower.
This study shows an association between suboptimal urate control and frequent hospital admission. Although causality cannot be proven by this retrospective study, this finding suggests that inadequate long-term gout treatment may have important adverse consequences, both for the patient with respect to pain and disability, but also for health care organizations with expense related to preventable unplanned hospital admissions.
Most patients admitted were of Maori or Pacific ethnicity, reflecting the severe gout that is documented in these populations. 16, 18 This factor was specifically controlled for as part of the study design by matching control patients for age, sex, and ethnicity. Thus, we believe that our results can be generalized to other patient groups, although data from other units will be of interest.
Although the number of patients in our institution with at least 1 unplanned hospital admission over the 5 year study period with gout was high (707 patients), the sample size of this analysis was relatively small. The specific aim of this study was to characterize the relatively rare patients who are frequently admitted to hospital with gout. Although this group comprised only 6.8% of all of those with hospital admissions for gout, this is an instructive and clinically important group due to their poor disease control and high resource utilization.
Identification of cases in this study was restricted to those with acute gout attacks that required hospital treatment. As patient information was limited to hospital records, episodes of acute gout that were managed in the community were not able to be recorded. Consequently, it is not clear whether the cases and controls had the same total number of episodes of acute gout (but cases were admitted and controls were not) or whether the cases indeed had a greater number of episodes of acute gout. In either case, it is likely that the cases' higher comorbid disease burden was a significant factor in determining how episodes were managed.
This study has focused on the biologic factors associated with recurrent hospital admissions for gout treatment. Many other factors may also impact on repeated hospitalization for chronic diseases such as gout. Studies examining factors associated with unplanned readmissions for other chronic medical conditions have shown that in addition to disease severity and medical comorbidity, psychosocial factors are associated with repeated hospitalization. 19 -21 Given the high rates of recurrent hospital admissions for both gout and for other medical diseases in this study, it seems probable that psychosocial factors such as social support, psychologic wellbeing, selfmanagement strategies, and financial resources also play a role. The retrospective nature of this study did not allow for analysis of socio-economic and psychosocial factors. Prospective studies examining the importance of psychosocial factors in the management of gout are needed to further clarify this relationship.
Selection of a suitable control group for such a study can be problematic. We selected a control group with no gout-related hospital admissions in an attempt to identify a group of patients with relatively good gout control. Control patients were identified from rheumatology clinics to account for the more complex disease that is treated in secondary care, in both the ambulatory and inpatient setting. Indeed, one of the most interesting findings in this study is not the differences between the cases and controls, but the similarities. Despite patient matching, similar disease duration and similar rates of renal impairment, hypertension, and diabetes, the control patients achieved much better gout management and avoided hospital admission. This observation should offer some optimism to those patients with poorly controlled gout and frequent hospital admissions, and their physicians. It is possible that renewed efforts aimed at effective prophylaxis and urate-lowering therapy may help these patients prevent frequent acute attacks and the need for hospitalization. Prospective studies are needed to investigate this hypothesis.
Despite the potential limitations of this study, our observations have important health implications for patients with gout and their health care providers. With less than half of the cases on urate-lowering therapy and even fewer on doses high enough to achieve disease control, this study highlights the problems of translating gout treatment guidelines into clinical practice. Initiating and intensifying urate-lowering therapy may be difficult to coordinate between primary care providers, rheumatologists, and other hospital-based physicians, especially where multiple comorbidities exist. Coordination of effective gout management for such complex patients is challenging, but may prove crucial for optimal patient care and prevention of recurrent hospital admissions.
